Validity of Serum Cystatin c for Prediecting Obesity Nephropathy

Background: Serum concentration of cystatin C a marker of glomerular filtration has been associated with cardiovascular disease (CVD). The aim of this study was To evaluate cystatin C as a marker of obese patients without chronic kidney disease (CKD).Materials and Methods: The study population consisted of 36 subjects with metabolic syndrome and 32 subjects free of metabolic syndrome (control group). HDL-C, LDL-C, blood urea, triglycerides, glucose, HbA1c, serum cystatin C and serum creatinine were measured in both groups. GFR was calculated in both groups using Cockroft–Gault equation. Results: Obese patients presented higher cystatin C levels than normal samples (1.28 ±0.29, p<0.05). In the binary logistic regression, the presence of Obese patients was significantly associated with elevated cystatin C levels. Conclusion: Our results suggests that cystatin C may be a marker for Obese patients and may identify a certain degree of renal dysfunction even when serum creatinine does not exceed normal level. In this study we demonstrated that serum creatinineand GFR did not differ significantly between diabetic and control group serum concentration of cystatin C was significantly higher in diabetic group compared with control group. The strengths of this study are the evaluation of reliability, and sensivity incomparison with a ‘routine test of GFR in an adequately study. The methodology used allows appropriate statistical comparisons of reliabilityin contrast to most other previous evaluations of GFR.